Phase 2 Trial of Leflunomide in Patients With High-Risk Smoldering Multiple Myeloma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Leflunomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 12 Nov 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Oct 2019 Planned initiation date changed from 11 Sep 2019 to 11 Dec 2019.
- 03 Jul 2019 Planned initiation date changed from 11 Jun 2019 to 11 Sep 2019.